Should I Buy RNXT? RNXT 2026 Analysis

Should You Buy RenovoRx Inc (RNXT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.990

1 Day change

4.10%

52 Week Range

1.450

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

RNXT is not a good buy right now for an impatient investor. Despite a positive analyst initiation and upcoming catalysts (conference presentation and earnings), the technical setup remains bearish (SMA200 > SMA20 > SMA5) with no Intellectia buy signals today, implying unfavorable timing for immediate entry. A better buy case would require a clean break and hold above ~$1.05 (R1) with improving momentum; until then, it’s a hold/speculative watch rather than a chase at ~$0.98.

Technical Analysis

Price/Trend: RNXT is trading around $0.98 (+3.08% regular session; +4.0% pre-market) but remains in a broader bearish structure given bearish moving average alignment (SMA200 > SMA20 > SMA5), which typically signals an established downtrend or weak recovery. Momentum: MACD histogram is negative (-0.0125) but contracting (selling pressure easing), suggesting downside momentum is slowing, not reversed. RSI(6) ~46.9 is neutral, indicating no strong oversold bounce signal. Levels: Pivot ~0.971 (price is just above). Support: S1 ~0.896, S2 ~0.85. Resistance: R1 ~1.045 then R2 ~1.091. For an impatient buy, the technical “prove it” level is a decisive move above ~1.045 with follow-through; otherwise, risk of slipping back toward ~0.90 remains. Pattern-based forward view (provided): Similar-pattern stats imply ~70% chance of a small dip next day (-0.49%), modestly positive bias over 1 week (+0.83%) and 1 month (+3.49%), but these are small edges and do not override the bearish trend structure.

Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

on optimizing chemotherapy delivery with the double-balloon catheter; conference exposure can act as a sentiment catalyst.

Neutral/Negative Catalysts

with MACD still below zero; rallies may be sold until trend flips.
could disappoint if revenue growth remains minimal or losses widen.

Financial Performance

Latest reported quarter provided: 2025/Q3.

Revenue: $266K (reported as up 0.00% YoY), indicating very small scale commercial revenue and limited acceleration in the snapshot.
Net income: -$2.912M (improved 17.85% YoY), suggesting some reduction in losses.
EPS: -$0.08 (down 20% YoY), indicating per-share loss worsened despite the net income improvement (likely share count effects and/or other items).
Gross margin: 80.08% (flat YoY), which is strong structurally, but the key issue is scaling revenue meaningfully. Overall: early commercialization with high gross margin potential, but still loss-making with very low revenue base; the growth trend in the snapshot is not yet convincing.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst actions trend: still net-positive with Buy ratings, but mixed on targets.

2026-01-29: JonesResearch initiated coverage with Buy and an $8 price target (bullish, highlights FDA-cleared RenovoCath and potential utility in pancreatic cancer treatment delivery).
2025-11-14: Alliance Global reiterated Buy but cut PT to $3 from $3.50 due to lower forecasts and modestly higher expected dilution. Wall Street pros vs cons (from the above): Pros: FDA-cleared device, early commercial sales traction, potential oncology use-case expansion narrative, and supportive Buy ratings. Cons: dilution/financing risk is explicitly noted by at least one firm, and revenue scale remains very small relative to losses.

4 Analyst Rating

Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is 5.63 USD with a low forecast of 3 USD and a high forecast of 12.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.951

Low

Averages

5.63

High

12.5

Current: 0.951

Low

Averages

5.63

High

12.5

JonesResearch

Justin Walsh

initiated

AI Analysis

2026-01-29

Reason

JonesResearch

Justin Walsh

Price Target

AI Analysis

2026-01-29

initiated

Reason

JonesResearch analyst Justin Walsh initiated coverage of RenovoRx with a Buy rating and $8 price target. RenovoRx is a commercial stage medical technology company with an FDA-cleared dual-balloon catheter, RenovoCath, designed to improve delivery of anti-cancer drugs to tumors with poor blood supply, the analyst tells investors in a research note. The firm sees the device being "particularly useful" for treating pancreatic cancer.

Alliance Global

Buy

maintain

2025-11-14

Reason

Alliance Global

Price Target

2025-11-14

maintain

Buy

Reason

Alliance Global lowered the firm's price target on RenovoRx to $3 from $3.50 and keeps a Buy rating on the shares after the company reported Q3 earnings that were within expectations. The firm cites lower forecasts and modestly higher expected dilution for its reduced target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RNXT

Unlock Now

RNXT Should I Buy

RNXT Should I Buy

Should You Buy RenovoRx Inc (RNXT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch